BioInvent International AB
https://www.bioinvent.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioInvent International AB
BioInvent Using New Screening Platforms To Identify Novel IO Targets
Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.
Storm Coming? Commercial Compliance Crackdown Shocks China Pharma Industry
In a new wave of crackdowns on compliance in the pharma sector in China, 10 medical meetings have been cancelled in short order, while sector-wide stock prices have plunged and 100 hospital officials placed under investigation, shocking the industry.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Bioinvent Finans AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice